Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OTL-101 Gene Therapy for ADA-SCID
NCT03765632Phase 2Completed
- Sponsor
- Great Ormond Street Hospital
- Start
- Jan 2018
- Primary completion
- Sep 2021
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of simoladagene autotemcel in severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), sponsored by Great Ormond Street Hospital. Started Jan 2018; status: completed.
02
Drugs
simoladagene autotemcel
03
Conditions
severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID)
Beyond the preview
Go deeper on NCT03765632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765632.